...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Clinical Interventions in Aging >Plasma Interleukin-37 is Elevated in Acute Ischemic Stroke Patients and Probably Associated With 3-month Functional Prognosis
【24h】

Plasma Interleukin-37 is Elevated in Acute Ischemic Stroke Patients and Probably Associated With 3-month Functional Prognosis

机译：血浆白细胞介素-37在急性缺血性卒中患者中升高，可能与3个月的功能预后相关

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: Interleukin-37 is a novel cytokine emerging as a natural suppressor of inflammatory responses. Inflammation and the immune response play important roles in acute ischemic stroke. This study aimed at evaluating the plasma levels and the association with 3-month outcomes of interleukin-37 in acute ischemic stroke patients. Patients and Methods: In total, 152 consecutive patients with acute ischemic stroke and 45 healthy controls were included. Plasma interleukin-37 levels were determined in the first morning after admission using an enzyme-linked immunesorbent assay. The primary outcome was the 3-month functional outcome (modified Rankin Scale score 2). Logistic regression was used to evaluate the risk and 3-month outcome of stroke according to plasma interleukin-37 level. Results: Plasma interleukin-37 levels were significantly higher in the patients with acute ischaemic stroke than in the healthy controls (182.26 versus 97.89 pg/mL, p 0.001). Patients with large-artery atherosclerosis had significantly higher IL-37 levels than those with small-artery occlusion (202.12± 35.82 versus 175.67± 33.71pg/mL, p 0.001). Plasma interleukin-37 levels were positively correlated with National Institutes of Health Stroke Scale scores (r=0.521, p 0.0001) and lesion volume (r=0.442, p 0.0001). Ninety-four and 58 patients had favourable and unfavourable 3-month outcomes, respectively. Elevated plasma interleukin-37 levels were independently associated with unfavourable 3-month outcomes (adjusted odds ratio=1.033, p =0.001, 95% confidence interval: 1.015– 1.056). Conclusion: Admission plasma interleukin-37 levels were significantly increased after acute ischemic stroke. Elevated interleukin-37 levels were independently associated with unfavourable 3-month prognoses in acute ischemic stroke patients. Further studies with other populations are needed.
机译：背景：白细胞介素-37是一种作为炎症反应的天然抑制的新型细胞因子。炎症和免疫反应在急性缺血性卒中起重要作用。该研究旨在评估血浆水平和与急性缺血性卒中患者中白细胞介素-37的3个月结果的关联。患者和方法：总共152例连续患有急性缺血性卒中患者和45例健康对照。使用酶联免疫吸附测定释放后，在第一次早晨测定血浆白细胞介素-37水平。主要结果是3个月的功能结果（改进的Rankin Scade Score> 2）。根据血浆白细胞介素-37水平，使用逻辑回归评估卒中风险和3个月的结果。结果：急性缺血性卒中患者血浆白细胞介素-37水平显着高于健康对照（182.26与97.89pg / ml，P <0.001）。大动脉动脉粥样硬化的患者显着高于小动脉闭塞的IL-37水平（202.12±35.82与175.67±33.71pg / ml，p <0.001）。血浆白细胞介素-37水平与国家健康卒中量表评分（r = 0.521，p <0.0001）和病变体积（r = 0.442，p <0.0001）呈正相关。九十四和58名患者分别有利和不利的3个月成果。升高的血浆白细胞介素-37水平与不利的3个月结果单独相关（调节的赔率比= 1.033，p = 0.001,95％置信区间：1.015- 1.056）。结论：急性缺血性卒中后入学血浆白细胞介素-37水平显着增加。白细胞介素-37水平升高与急性缺血性卒中患者的不利3个月的预期无关。需要与其他人群进行进一步研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号